ImPact Biotech is a biotechnology company focusing on the development and launch of Padeliporfin Vascular Targeted Photodynamic (VTP) therapy, a minimally invasive platform technology for the treatment of solid tumours. Padeliporfin, a chlorophyll derivative, intravenously delivered, inactive photosensitizer drug, was developed by Prof. Avigdor Schertz of the Department of Plant and Environmental Sciences,
and the late Prof. Yoram Salomon of the Department of Biological Regulation, both at the Weizmann Institute of Science.

ImPact Biotech is at the forefront of the biotechnology industry. We work to develop precise, safe & effective, and convenient new therapeutic solutions which will allow thousands of patients to confidently face the challenges of cancer while maintaining their quality of life. Our technology, Padeliporfin VTP therapy, offers and organ-sparing treatment with surgery-like efficacy, where surgery is debilitating or where the patient is ineligible.

Our vision is for Padeliporfin VTP to become the new standard of care for the treatment of a wide range of otherwise difficult to treat and often rare solid tumors, beginning with Upper Tract Urothelial cancer and progressing to certain types of Lung cancer, and Pancreatic cancer.

Link to website:                         https://impactbiotech.com/

Link to Linkedin page :             Impact Biotech Linkedin Page